louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05662072: Motor Imagery and Action Observation in Respiratory Training
Official title: Effects of Motor Imagery and Action Observation on Respiratory Parameters
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Respiratory Function
Motor Imagery
Action Observation Training
Lead sponsor: Cardenal Herrera University
Sponsor class: OTHER
First posted: 2022-12-22
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The principal aim of this study was to asses the effects of motor imagery and action observation training on ventilatory and functional capacity through a randomized controlled trial.


Eligibility criteria: Inclusion Criteria:

* Age between 18 and 60
* Healthy and with no respiratory pathology subjects

Exclusion Criteria:

* Any cognitive impairment that hindered viewing of audiovisual material.
* Difficulty understanding or communicating.
* Presence of systemic pathology, Central Nervous System or rheumatic disease.
* Inadequate understanding of the Spanish language to follow instructions for measuring and treatment.
* Collaboration of pregnant women.
* Underage subject

Primary outcomes:
measure: Change from Forced vital capacity physiological parameter
timeFrame: Preintervention and postintervention (after the 10 minutes intervention)
measure: Change from FEV1 physiological parameter
timeFrame: Preintervention and postintervention (after the 10 minutes intervention)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04555772: Evaluation of Factors That Cause Secondary Brain Damage on Mortality and Morbidity in Patients Undergoing Emergency Surgery Due to Head Trauma.
Official title: Evaluation of Factors That Cause Secondary Brain Damage on Mortality and Morbidity in Patients Undergoing Emergency Surgery Due to Head Trauma.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Brain Injuries
Keywords: secondary brain damage
electrolyte imbalance
head trauma
Lead sponsor: Turkish Society of Anesthesiology and Reanimation
Sponsor class: OTHER
First posted: 2020-09-21
Enrollment: 108
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: they collect data of 108 patients who admitted to Bursa Uludag University hospital between 2013 and 2018 and were diagnosed with traumatic brain injury and operated within the first 24 hours after admission.

Brief summary: Traumatic brain injury is combination damage that occurs as a result of a chain reaction of various metabolic events that develop after primary damage caused by trauma. Pathological events such as lactic acidosis, electrolyte imbalance, increased inflammation that occur during traumatic brain injury leads to poor prognosis in patients.

The retrospective study was conducted to investigate the effect of factors that may cause secondary damage, especially electrolyte imbalance and blood glucose levels, on mortality and morbidity in patients undergoing emergency surgery due to head trauma.


Eligibility criteria: Inclusion Criteria:

* patients who admitted to Bursa Uludag University hospital between 2013 and 2018
* patients diagnosed with traumatic brain injury and operated within the first 24 hours after admission

Exclusion Criteria:

* pediatric patients
* patients that operated after 24 hour of admission

Primary outcomes:
measure: mortality and morbidity in patients who underwent emergency operation within 24 hours after traumatic brain injury
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bursa
country: Turkey
facility: Bursa uludag university
Study officials:
References:
Clinical trial NCT01932372: Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis
Official title: XELJANZ (REGISTERED) TABLETS 5MG SPECIAL INVESTIGATION (ALL-CASES SURVEILLANCE)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rheumatoid Arthritis
Keywords: Rheumatoid Arthritis
Good Post Marketing Study Practice
Tofacitinib
Xeljanz
Regulatory Post Marketing Commitment Plan
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2013-08-30
Enrollment: 9968
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to over 8 mg Methotrexate for 3 months treatment.

Brief summary: The objective of this Surveillance is to verify the following subject matters concerning Tofacitinib (Xeljanz) under general practice.

1) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy 2） Long-term safety (particularly, malignant tumors and serious infections) and efficacy

Occurrences of malignant tumors and serious infections will be compared with a control group.

Detailed description: All the patients whom an investigator prescribes the Xeljanz or Standard of Care for rheumatoid arthritis should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Eligibility criteria: Inclusion Criteria:

* All patients receiving Tofacitinib (Xeljanz)

Exclusion Criteria:

Not Applicable

Primary outcomes:
measure: Percentage of Participants With Treatment-related Adverse Events or Serious Treatment-related Adverse Events in Participants Who Received XELJANZ
timeFrame: 36 months
measure: Change in Disease Activity Based on Simplified Disease Activity Index (SDAI)
timeFrame: Baseline, 1, 6, 12, 24, 36 months
measure: Change in Disease Activity Score Based on 28-joints Count (DAS28)
timeFrame: Baseline, 1, 6, 12, 24, 36 months
Secondary outcomes:
measure: Occurrence of Serious Infection Events
timeFrame: 12 months
measure: Occurrence of Malignancy
timeFrame: 36 months
measure: Occurrence of Death
timeFrame: 36 months
Other outcomes:
Locations:
city: Tokyo
country: Japan
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT05142072: Design and Application of Vitamin D Films for Burn Healing After Cauterizing Surgery
Official title: Formulation, Characterization and In-vivo Evaluation of Controlled Release Intranasal Films of Vitamin D3 as an Optimistic Dosage Form for Rapid and Effective Healing of Cauterized Turbinectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Nasal Obstruction
Lead sponsor: Deraya University
Sponsor class: OTHER
First posted: 2021-12-02
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: One of this method's drawbacks is the healing of cauterized cartilage after processing. It was reported that the healing is so slow as no dosage form can reach this place in addition to the scares produced from healing is very irritable to the patient.

From this point, the investigators start searching for a solution to this problem and reach the repositioning of Vitamin D3 (calciferol) as an active ingredient for the rapidity and efficacy of burn healing.

The dosage form of choice that was reported before for intranasal application by the same team of investigators and gave good results. the intranasal films were proved for its convince, simplicity, efficacy, and compliance to patients.


Eligibility criteria: Inclusion Criteria:

* patients complain of nasal obstruction
* do not respond to medications
* treatment need surgery
* patients accept following up in a timely manner for 3 weeks

Exclusion Criteria:

* no nasal polyps,
* have problems with the surgical procedures
* have allergy with any of the treatment components (vitamin D3 or chitosan)
* don't follow instructions or miss the following up

Primary outcomes:
measure: Healing of cauterized tissues after surgery procedures
timeFrame: three week
Secondary outcomes:
measure: patients compliance from the new dosage form
timeFrame: three weeks
measure: Assessment of grades of healing by ENT surgeon
timeFrame: three weeks
Other outcomes:
Locations:
city: Minya
country: Egypt
facility: Minya university, faculty of medicin
state: المنيا
Study officials:
References:
Clinical trial NCT05235672: Detection of LADA in a Hospital in the Mexican Southeast
Official title: Detection of Latent Autoimmune Diabetes in Adults, Clinical and Metabolic Profile in Patients Treated at the Diabetes Clinic in a Hospital in the Mexican Southeast.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Latent Autoimmune Diabetes
Keywords: LADA
GADA
Mexican population
Lead sponsor: Universidad Juárez Autónoma de Tabasco
Sponsor class: OTHER
First posted: 2022-02-11
Enrollment: 110
Sex: ALL
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects were initially diagnosed and received pharmacological treatment for T2D. In addition, these patients presented clinical and biochemical characteristics both of T1D and T2D, progressing to insulin dependency. Such individuals were invited to participate in the study. An endocrinologist diagnosed and evaluated all these patients.

Brief summary: Patients with Latent Autoimmune Diabetes in Adults (LADA) show autoantibodies that indicate an autoimmune pathogenesis. Glutamic acid decarboxylase autoantibodies (GADA) are most prevalent islet autoantibodies in European patients with LADA. In this sense, it is considered that it is sufficient to determine GADA to identify subjects with LADA from patients with T2D for research purposes. Therefore, the aim was to investigated the presence of GADA in serum of subjects with T2D and its relationship with clinical criteria, metabolic control, drug treatment, and diabetes complications to identify possible patients with LADA in a hospital in southeastern Mexico is worthwhile.

The sample was recruited at the Diabetes Clinic of the Regional Hospital of High Specialty "Dr. Gustavo A. Rovirosa Pérez", in the period from January 2020 to May 2021. The diagnosis was based in accordance with World Health Organization (WHO, 1999) criteria. Inclusion criteria: 1) patients previously diagnosed with T2D, 2) absence of insulin requirement for at least 6 months after diagnosis, 3) \> 30 and \< 50 years old at diabetes diagnosis, 4) BMI \< 40 kg/m2, 5) subjects who agreed to participate in the study and signed the informed consent before the interview.

Serum GADA and other biochemical concentrations were determined by an enzymatic immunoassay method (Human Anti-Glutamic Acid Decarboxylase ELISA Kit; MyBioSource).


Eligibility criteria: Inclusion Criteria:

* patients previously diagnosed with T2D,
* absence of insulin requirement for at least 6 months after diagnosis,
* \> 30 and \< 50 years old at diabetes diagnosis,
* BMI \< 40 kg/m2,
* subjects who agreed to participate in the study and signed the informed consent before the interview.

Exclusion Criteria:

• patients with other types of diabetes, and subjects who did not agree to participate.

Primary outcomes:
measure: GADA in serum of subjects with T2D
timeFrame: May 2021
Secondary outcomes:
Other outcomes:
Locations:
city: Villahermosa
country: Mexico
facility: Isela Esther Juarez Rojop
state: Tabasco
Study officials:
References:
Clinical trial NCT06989372: Serratus Posterior Superior Intercostal Plane Block, Versus Erector Spinae Facial Plane Blocks
Official title: Serratus Posterior Superior Intercostal Plane Block, Versus Erector Spinae Facial Plane Blocks A Comparative Study for Postoperative Pain Control and Opioid Consumption for Patient Undergoing Modified Radical Mastectomy Surgery
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Breast Surgery
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2025-05-25
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Mastectomy is currently the most effective treatment for breast cancers in women. postoperative pain management carries a high degree of difficulty, as the breast has complex innervation involving the intercostal (T1-T7), superficial cervical plexus (supraclavicular nerves) and brachial plexus .While severe acute pain is observed in approximately 40% of post-mastectomy patients, moderate-to-severe pain is observed in almost one-third of them .


Eligibility criteria: Inclusion Criteria:

* age 18 to 65 years
* ASA classification I and II

Exclusion Criteria:

* age below 18 or above 65 years
* ASA classification III or more

Primary outcomes:
measure: Morphine consumption
timeFrame: 24 hours post operatively
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams university
Study officials:
References:
Clinical trial NCT01873872: Evaluation of Probiotics and the Development of Clostridium Difficile Associated Diarrhea in Patients Receiving Antibiotics
Official title: Evaluation of Probiotics and the Development of Clostridium Difficile Associated Diarrhea in Patients Receiving Antibiotics
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Development of Clostridium Difficile Associated Diarrhea
Lead sponsor: St. Vincent's East, Birmingham, Alabama
Sponsor class: OTHER
Collaborators: name: Master Supplements, Inc
First posted: 2013-06-10
Enrollment: 120
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: We have designed this study to measure the effect of normal flora supplementation, using available probiotics, on the incidence of Clostridium difficile-associated diarrhea

in a population of general inpatients who are receiving antibiotics.

Detailed description: General medical-surgical patients in a community hospital who are receiving antibiotics, and who agree to participate, will be given one of two different probiotics, or placebo. Data will be gathered during their hospitalization, and at one and three months following hospital discharge. We expect to see a lower incidence of Clostridium difficile-associated diarrhea in the probiotic groups when compared to the placebo group. We will also be looking for differences between the effects of the two probiotics, which differ in strain types and number of colony forming units per dose.

Eligibility criteria: Inclusion Criteria: Any hospitalized patient who is age 19 or older and receiving antibiotics.

-

Exclusion Criteria:

* Feeding tube in place
* Pregnancy
* Milk or soy allergy
* Sensitivity to lactose
* Immunocompromised defined as:

  1. Absolute neutrophil count (ANC) ≤ 500 cells/mm3
  2. HIV
  3. Cancer patient receiving chemotherapy or radiation therapy
  4. Immune deficiency
  5. Post organ transplant

Participants will be withdrawn from the study if they develop any of the exclusion criteria during the hospitalization.

-

Primary outcomes:
measure: Development of Clostridium difficile associated diarrhea in patients receiving antibiotics
timeFrame: Up to six months
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: St. Vincent's East
state: Alabama
Study officials:
affiliation: St. Vincent's East
name: Leanne Phillips, Pharm.D
role: PRINCIPAL_INVESTIGATOR
affiliation: St. Vincent's East
name: Walter Ross, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: St. Vincent's East
name: Mark Middlebrooks, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: St. Vincent's East
name: Lee Wimberly, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: St. Vincent's East
name: Linda Adams, RPh
role: PRINCIPAL_INVESTIGATOR
affiliation: St. Vincent's East
name: Carrie Castleberry, RN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02334072: The Effects of Different Airway Devices on Middle Ear Pressure in Pediatric Patients
Official title: The Effects of Different Airway Devices on Middle Ear Pressure in Pediatric Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Local Pressure Effects
Simple Ear
Lead sponsor: Adiyaman University Research Hospital
Sponsor class: OTHER
First posted: 2015-01-08
Enrollment: 100
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Even though the effects of anesthetic agents both inhalation and intravenous have been well described, the effect of laryngeal mask airways haven't. The purpose of the study is to determine the effects of different types of laryngeal mask airways on middle ear pressure.

Detailed description: All the patients in each group of laryngeal mask airway will contain 20 patients. In all groups middle ear pressures will be measured, in both right and left ear, preoperatively, after induction of anesthesia, insertion of laryngeal mask and in 1st., 5th., 10th. minutes and every 5 minutes perioperatively and recorded. Also the heart rates,arterial oxygen saturation (SaO2), airway pressures and end-tidal carbon dioxide values will be recorded before and following induction of anesthesia and in 1st., 5th., 10th. minutes and every five minutes perioperatively. Patients will be followed during the hospital stay for any complications.In all groups premedication will be done with midazolam. Anesthesia will be inducted with propofol and fentanyl; and maintained with sevoflurane-air combination.

Eligibility criteria: Inclusion Criteria:

* Elective patients undergoing subumbilical surgery under general anesthesia

Exclusion Criteria:

* Emergency conditions
* Rejection of patient approval
* Tympanic membrane perforation history
* Anticipated difficult airway
* Contraindications for LMA application

Primary outcomes:
measure: Middle ear pressure changes after the device application (MEP)
timeFrame: Perioperative
Secondary outcomes:
measure: Composite Hemodynamics
timeFrame: Perioperative
Other outcomes:
Locations:
city: Adiyaman
country: Turkey
facility: Adiyaman University Research Hospital
Study officials:
affiliation: Adiyaman University Research Hospital
name: Ruslan Abdullayev
role: STUDY_DIRECTOR
References:
Clinical trial NCT04541472: Influence of the COVId-19 Pandemic on the STRESS of Dental Surgeons (COVISTRESS - Dental Surgery)
Official title: Influence of the COVId-19 Pandemic on the STRESS of Dental Surgeons
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Dental Surgeon
Keywords: COVID-19
Dental surgery
Stress
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
First posted: 2020-09-09
Enrollment: 1000
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Dental surgeons and associates

Brief summary: Coronavirus has caused containment of more than half of the world's population and a major and rapid reorganization of clinical and support services. The spread of coronavirus (COVID-19) has posed significant challenges for dental surgeons and associates who are at high risk of COVID-19 infection due to close face-to-face contact. However, there is currently no data on the influence of this epidemic on the practice and feelings of dental surgeons and associates

Detailed description: This is an observational study by REDCap questionnaire® via an internet link, which will be distributed to dental surgeons and associates by any means The self-survey will assess stress, working conditions and changes in practices related to the coronavirus outbreak. This Dental Surgery questionnaire includes 16 questions

Eligibility criteria: Inclusion Criteria:

* All dental surgeons and associates volunteers to participate

Exclusion Criteria:

* None

Primary outcomes:
measure: Stress measures
timeFrame: Day 1
Secondary outcomes:
measure: Sociodemographic characteristics
timeFrame: Day 1
measure: occupation perception
timeFrame: Day 1
measure: work conditions
timeFrame: Day 1
measure: Changes in practices
timeFrame: Day 1
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: University Hospital, Clermont Ferrand
Study officials:
References:
Clinical trial NCT06144372: Extracorporeal Shockwave Lithotripsy, Electroconductive and Electrohydraulic Types
Official title: Comparison of Efficacy and Safety of Extracorporeal Shockwave Lithotripsy: A Randomized, Controlled Trial Study of Electroconductive and Electrohydraulic Types
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Urolithiasis
Keywords: Extracorporeal shockwave lithotripsy
Urolithiasis
Radiation Exposure
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2023-11-22
Enrollment: 56
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy and safety of electroconductive (EC) and electrohydraulic (EH) extracorporeal shock wave lithotripsy (ESWL) for the treatment of ureter and kidney stones, this study conducted a randomized controlled trial.


Eligibility criteria: Inclusion Criteria:

* The analysis included cases of stones in the upper kidney and ureter, with diameters ranging from 5 mm to 15 mm.

Exclusion Criteria:

* Patients with musculoskeletal deformities, ongoing urinary tract infections requiring prioritized infection treatment, blood clotting disorders, and ureteral obstruction that made stone expulsion difficult were excluded from the study.

Primary outcomes:
measure: age
timeFrame: 2 weeks
measure: Gender
timeFrame: 2 weeks
measure: height
timeFrame: 2 weeks
measure: weight
timeFrame: 2 weeks
measure: smoking
timeFrame: 2 weeks
measure: drinking
timeFrame: 2 weeks
measure: Diabetes mellitus
timeFrame: 2 weeks
measure: Hypertension
timeFrame: 2 weeks
measure: Preoperative Double J stent
timeFrame: 2 weeks
measure: creatinine
timeFrame: 2 weeks
measure: Glomerular Filtration Rate
timeFrame: 2 weeks
measure: hemoglobin
timeFrame: 2 weeks
measure: Hydronephrosis grade
timeFrame: 2 weeks
measure: Analgesic
timeFrame: 2 weeks
measure: stone size
timeFrame: 2 weeks
measure: Stone laterality
timeFrame: 2 weeks
measure: Stone location
timeFrame: 2 weeks
measure: Stone volume
timeFrame: 2 weeks
measure: Stone shape
timeFrame: 2 weeks
measure: Stone to skin distance
timeFrame: 2 weeks
measure: Hounsfield unit
timeFrame: 2 weeks
measure: Urine color
timeFrame: 2 weeks
measure: Urine Turbidity
timeFrame: 2 weeks
measure: Urine Specific Gravity
timeFrame: 2 weeks
measure: Urine pH
timeFrame: 2 weeks
measure: Intensity
timeFrame: 2 weeks
measure: Used power
timeFrame: 2 weeks
measure: Shock
timeFrame: 2 weeks
measure: Speed
timeFrame: 2 weeks
measure: Visual analog scale for pain
timeFrame: 2 weeks
measure: Satisfaction score
timeFrame: 2 weeks
measure: Stone-free rates (%)
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
citation: Motolova M, Kral M. Effect of targeting and generator type on efficacy of extracorporeal shock wave lithotripsy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 Dec;166(4):434-440. doi: 10.5507/bp.2022.029. Epub 2022 Jun 27.